Literature DB >> 28848905

Nebulized Long-Acting Beta2-Agonists: More Than Just Bridging Gaps in the Management of Symptomatic COPD.

Daniel A Gerardi1, Nicholas J Gross2.   

Abstract

Entities:  

Keywords:  LABAs; chronic obstructive pulmonary disease; copd; long-acting beta2-agonists

Year:  2017        PMID： 28848905      PMCID： PMC5560244          DOI： 10.15326/jcopdf.4.1.2016.0175

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  4 in total

1.  Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Authors:  Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin
Journal:  Chronic Obstr Pulm Dis       Date:  2016-11-15

2.  Inhaled therapy in elderly COPD patients; time for re-evaluation?

Authors:  Sheba Jarvis; Philip W Ind; Robert J Shiner
Journal:  Age Ageing       Date:  2007-01-31       Impact factor: 10.668

Review 3.  Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD.

Authors:  Wouter H van Geffen; W R Douma; Dirk Jan Slebos; Huib A M Kerstjens
Journal:  Cochrane Database Syst Rev       Date:  2016-08-29

4.  Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.

Authors:  James F Donohue; N A Hanania; C Fogarty; S C Campbell; M Rinehart; K Denis-Mize
Journal:  Ther Adv Respir Dis       Date:  2008-08       Impact factor: 4.031
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.